Production (Stage)
Sagimet Biosciences Inc.
SGMT
$3.55
$0.051.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 2.00M | 2.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 2.00M | 2.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 0.00 | 2.00M | 2.00M |
| SG&A Expenses | 17.03M | 16.01M | 15.84M | 16.09M | 14.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.55M | 54.45M | 45.73M | 38.28M | 34.74M |
| Operating Income | -65.55M | -54.45M | -45.73M | -36.28M | -32.74M |
| Income Before Tax | -57.11M | -45.57M | -37.52M | -29.25M | -27.92M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.11 | -45.57 | -37.52 | -29.25 | -27.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.11M | -45.57M | -37.52M | -29.25M | -27.92M |
| EBIT | -65.55M | -54.45M | -45.73M | -36.28M | -32.74M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.78 | -1.44 | -1.29 | -1.18 | -36.73 |
| Normalized Basic EPS | -1.11 | -0.90 | -0.80 | -0.74 | -22.95 |
| EPS Diluted | -1.78 | -1.44 | -1.29 | -1.18 | -36.73 |
| Normalized Diluted EPS | -1.11 | -0.90 | -0.80 | -0.74 | -22.95 |
| Average Basic Shares Outstanding | 128.45M | 125.29M | 116.54M | 102.59M | 70.87M |
| Average Diluted Shares Outstanding | 128.45M | 125.29M | 116.54M | 102.59M | 70.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |